Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: Identification of novel risk factors?

Medical Mycology

Volumn 48, Issue O1, 2010, Pages

  Blyth, Christopher C ^a,c   Middleton, Peter G ^a   Harun, Azian ^b   Sorrell, Tania C ^a   Meyer, Wieland ^a,b   Chen, Sharon C A ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

clinical risk factors; Cystic fibrosis; Scedosporium

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; FLUCLOXACILLIN; INTERNAL TRANSCRIBED SPACER; ITRACONAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ADULT; ARTICLE; ASPERGILLUS FUMIGATUS; COCULTURE; CORTICOSTEROID THERAPY; CULTURE MEDIUM; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG REEXPOSURE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNGAL COLONIZATION; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PANCREAS EXOCRINE INSUFFICIENCY; PETRIELLIDIUM BOYDII; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SCEDOSPORIUM AURANTIACUM; SCEDOSPORIUM PROLIFICANS; SPUTUM CULTURE;

ADULT; AUSTRALIA; CARRIER STATE; COHORT STUDIES; CULTURE MEDIA; CYSTIC FIBROSIS; DNA, RIBOSOMAL SPACER; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES, FUNGAL; MALE; MICROBIOLOGICAL TECHNIQUES; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTORS; SCEDOSPORIUM; SPUTUM; YOUNG ADULT;

ASPERGILLUS FUMIGATUS; BACTERIA (MICROORGANISMS); FUNGI; PSEUDALLESCHERIA; PSEUDALLESCHERIA BOYDII; PSEUDOMONAS AERUGINOSA; SCEDOSPORIUM; SCEDOSPORIUM AURANTIACUM; SCEDOSPORIUM PROLIFICANS;

EID: 78649971356     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.500627     Document Type: Article

References (38)

1. O'SulliVan BP, Freedman SD. Cysticf brosis. Lancet 2009; 373: 1891-1904.
2. Goss CH, Burns JL. Exacerbations in cysticf brosis 1: epidemiology and pathogenesis. Thorax 2007; 62: 360-367.
3. Koch C, Hoiby N. Diagnosis and treatment of cysticf brosis. Respiration. 2000; 67: 239-247.
4. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aerugi-nosa and other predictors of mortality and morbidity in young children with cysticf brosis. Pediatr Pulmonol 2002; 34: 91-100.
5. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance off la-mentous fungi in respiratory secretions of patients with cysticf brosis-a review. Med Mycol 2009; 47: 387-397.
6. Bouchara JP, Hsieh H Y, Croquefer S, et al. Development of an oligo-nucleotide array for direct detection of fungi in sputum samples from patients with cysticf brosis. J Clin Microbiol 2009; 47: 142-152.
7. Bargon J, Dauletbaev N, Kholer B, et al. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonisation in adult cysticf brosis patients. Respir Med 1999; 93: 835-838.
8. Lake FR, Tribe AE, McAleer R, Froudist J, Thompson PJ. Mixed allergic bronchopulmonary fungal disease due to Pseudallescheria boydii and Aspergillus. Thorax 1990; 45: 489-491.
9. Guignard S, Hubert D, Dupont B, et al. Multifocal Scedosporium apiospermum spondylitis in a cysticf brosis patient. J Cyst Fibros 2008; 7: 89-91.
10. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin MicrobiolRev 2005; 18: 44-69.
11. Symoens F, Knoop C, Schrooyen M, et al. Disseminated Scedospo-rium apiospermum infection in a cysticf brosis patient after double-lung transplantation. J Heart Lung Transplant 2006; 25: 603-607.
12. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolif cans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
13. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientif c Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.
14. Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21: 157-197.
15. Cimon B, Carrere J, Vinatier JF, et al. Clinical signif cance of Sce-dosporium apiospermum in patients with cysticf brosis. Eur J Clin-Microbiol Infect Dis 2000; 19: 53-56.
16. Williamson EC, Speers D, Arthur IH, Harnett G, Ryan G, Inglis TJ. Molecular epidemiology of Scedosporium apiospermum infection determined by PCR amplif cation of ribosomal intergenic spacer sequences in patients with chronic lung disease. J Clin Microbiol 2001; 39: 47-50.
17. Rainer J, Kaltseis J, de Hoog SG, Summerbell RC. Eff cacy of a selective isolation procedure for members of the Pseudallescheria boydii complex. Ant Van Leeuwenhoek 2008; 93: 315-322.
18. Gilgado F, Cano J, Gene J, Guarro J. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol 2005; 43: 4930-4942.
19. Gilgado F, Cano J, Gene J, Sutton DA, Guarro J. Molecular and phe-notypic data supporting distinct species statuses for Scedosporium ap-iospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol 2008; 46: 766-771.
20. Blyth CC, Harun A, Middleton PG, et al. Detection of occult Scedospo-rium species in respiratory tract specimens from patients with cysticf brosis by use of selective media. J Clin Microbiol 2010; 48: 314-316.
21. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirom-etry. Eur RespirJ 2005; 26: 319-338.
22. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187.
23. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of Clinical Microbiology. Washington: American Society for Microbiology, 2007.
24. De Hoog GS, Guarro J, Gene J, Figueras MJ. Atlas of Clinical Fungi. 2nd ed. Utrecht, The Netherlands: Centraalbureau voor Schimmelcul-tures, 2000: 305-310, 899-901.
25. Delhaes L, Harun A, Chen SC, et al. Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum. Emerg Infect Dis 2008; 14: 282-290.
26. Flume PA, O'SulliVan BP, Robinson KA, et al. Cysticf brosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969.
27. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised def nitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
28. Horre R, Marklein G, Siekmeier R, Nidermajer S, Reiffert SM. Selective isolation of Pseudallescheria and Scedosporium species from respiratory tract specimens of cysticf brosis patients. Respiration 2009; 77: 320-324.
29. Berenguer J, Rodriguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolif cans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolif cans Spanish Study Group. Medicine 1997; 76: 256-265.
30. Idigoras P, Perez-Trallero E, Pineiro L, et al. Disseminated infection and colonization by Scedosporium prolif cans : A review of 18 cases, 1990-1999. Clin Infect Dis 2001; 32: E158-E165.
31. Heath C, Slavin M, Sorrell TC, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Micro-biol Inf 2009; 15: 689-693.
32. Cano J, Guarro J, Mayayo E, Fernandez-Ballart J. Experimental infection with Scedosporium inf atum. J Med Vet Mycol 1992; 30: 413-420.
33. Gilgado F, Cano J, Gene J, Serena C, Guarro J. Different virulence of the species of the Pseudallescheria boydii complex. Med Mycol 2009; 47: 371-374.
34. Harrison F. Microbial ecology of the cysticf brosis lung. Microbiology 2007; 153: 917-923.
35. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbialf ora in patients with cysticf brosis. J Infect Dis 1999; 179: 1190-1196.
36. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cysticf brosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000; 16: 464-741.
37. Amin R, Dupuis A, Aaron SD, Ratjen F. The Effect of cinfection with Aspergillus fumigatus on lung function and hospitalisation in cysticf brosis patients. Chest 2010; 137: 171-176.
38. Sole A, Salavert M. Fungal infections after lung transplantation. Transplant Rev 2008; 22: 89-104.